Anti-Viral Drugs Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Report Description<br />
<strong>Anti</strong>-viral <strong>Drugs</strong> <strong>Market</strong>: Drivers and Restraints<br />
As of October 2013, according to WHO, there were around 35.3 Mn people globally,<br />
infected with HIV. Therefore, increased viral infection incidences is one of the important<br />
factors that drives the anti-viral drugs market growth. Because of the solid R&D activities,<br />
newer and advanced treatments and formulations, such as vaccines, combination<br />
therapy and others, are being introduced in the market. Hence, strong R&D is one of the<br />
crucial factors in the anti-viral drugs market growth. On the other hand, high risk of<br />
failure, high cost of R&D and therapy, and government austerity are some of threats<br />
expected to hinder the growth of market. These are some factors anticipated to fuel<br />
growth of global anti-viral drugs market within the forecast period of 2016-2026.<br />
However, increasing usage of natural products and high cost of developing drugs are the<br />
key challenges faced by the market.<br />
<strong>Anti</strong>-viral <strong>Drugs</strong> <strong>Market</strong>: Segmentation<br />
The global anti-viral drugs market is classified on the basis of product type, end user and<br />
geography.<br />
Based on product type, the global anti-viral drugs market is segmented into the<br />
following:<br />
• Hepatitis-C antivirals<br />
• HIV antivirals
Change language